CN1911280A - Hemostatic medicine used for cavitas uteri - Google Patents
Hemostatic medicine used for cavitas uteri Download PDFInfo
- Publication number
- CN1911280A CN1911280A CN 200610105022 CN200610105022A CN1911280A CN 1911280 A CN1911280 A CN 1911280A CN 200610105022 CN200610105022 CN 200610105022 CN 200610105022 A CN200610105022 A CN 200610105022A CN 1911280 A CN1911280 A CN 1911280A
- Authority
- CN
- China
- Prior art keywords
- medicine
- group
- fructus bruceae
- uteri
- cavitas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A styptic Chinese medicine for treating the metrorrhagia caused by functional disorder and menoxenia is prepared from brucea fruit oil, the extract of corydalis tuber and auxiliary.
Description
(1) technical field
The present invention relates to a kind of styptic for gynaecology, this medicine is an effective ingredient with Chinese medicine, makes medicament, is used for the treatment of menorrhagia, dripping urine endlessly, menostaxis, cycle disorder and irregular vagina bleeding.Sick function of dominant dysfunctional metrorrhagia.Especially a hemostatic medicine used for cavitas uteri.
(2) background technology
Functional disturbance metrorrhagia (abbreviation anovulatory dysfunctional uterine hemorrhage) is commonly encountered diseases, frequently-occurring disease and the difficult and complicated illness of childbearing age and climacteric women, account for the outpatient service prescription on individual diagnosis patient's of gynecological 10%, the relapse rate height, have a strong impact on numerous women's physical and mental health, become the focus that the department of obstetrics and gynecology worker pays close attention in the world wide.Therefore, it is imperative to try to explore to study the medicine for the treatment of metrorrhagia safely and effectively.
Menstruation is that stripping off of endometrical cycle is hemorrhage, and what of menstrual blood volume are directly proportional with endometrial area and thickness.The basic pathology of dysfunctional uterine hemorrhage is that the long and endometrium of endometrial hyperplasia is stripped off complete and caused abnormal uterine bleeding.
The method of treatment anovulatory dysfunctional uterine hemorrhage is a lot, traditional therapy be based on the treatment of the Chinese and western drugs of relief of symptoms with (or) examine and scrape.The nonresponder need go uterectomy.Uterectomy post-operative complication incidence rate is up to 30～40%.
Tradition traditional Chinese medical herbal treatment anovulatory dysfunctional uterine hemorrhage has certain curative effect, but varies with each individual, and treats loaded down with trivial detailsly, and the course of treatment is long, and still rests on the clinical observation on the therapeutic effect stage at present, does not form general theory, breakthrough is not arranged yet, based on oral decoction and pill on the form improvement.
Western medicine preparation does not still have the interior special-purpose medicine of cavity of uterus of state approval, but place the existing report of western medicine anovulatory dysfunctional uterine hemorrhage in the uterine cavity, its clinical efficacy and safety are still undetermined, pharmaceutical dosage form does not change, mostly be liquid two medicines, mobile strong, enter the abdominal cavity, to bring new misery to the patient, and be difficult to apply clinically.
Along with using the eighties in last century hysteroscope to hysterectomize since the inner membrance, the treatment of anovulatory dysfunctional uterine hemorrhage has had the development of advancing by leaps and bounds, and dispels the art treatment technology at endometrium and promotes day by day and use, and it is more and more wherein to dispel endometrial method by physiotherapy, as laser, microwave, radio frequency, hot-bulb, freezing etc., its effect certainly, but disposable apparatus costs an arm and a leg, some stabilization of equipment performance is poor, surgery cost is high, and complication is many, all need reach anesthesia in hospital, and the patient is difficult to accept.
(3) summary of the invention
The object of the invention provides a kind of treatment dysfunctional uterine bleeding, and symptom is: a hemostatic medicine used for cavitas uteri of menorrhagia, dripping urine endlessly, menostaxis, cycle disorder and irregular vagina bleeding.
The present invention is that we sum up the hysterectomize experience of inner membrance of physical method such as year hysteroscope surplus in the of ten, inspired by its thinking, the initiative Chinese medicine preparation is dispeled endometrium, to have corrosion wart, direct killing hyperplastic tissue cell, impel apoptotic Chinese medicine preparation to make ointment, disposable uterine cavity treatment anovulatory dysfunctional uterine hemorrhage, the new way of having opened up the treatment by Chinese herbs anovulatory dysfunctional uterine hemorrhage of being positioned over.
The present invention is to be the preparation that raw material is made with following medicine:
Oleum Fructus Bruceae 15～25% Rhizoma Corydalis extracts 9～15%
Above-mentioned Chinese medicine composition among the present invention is the active constituents of medicine of preparation medicine of the present invention.Fructus Bruceae hardship, cold has the effect of heat-clearing and toxic substances removing, corrosion wart.Modern pharmacological research shows that the Main Ingredients and Appearance of Oleum Fructus Bruceae is a unsaturated fatty acid, and they can directly enter cancerous cell, destroys plasma membrane system and mitochondrion, makes tumor cell disintegrate, death.Be widely used in clinical with abnormal cell proliferative diseases such as treatment malignant tumor and condyloma acuminatum.Rhizoma Corydalis suffering, hardship, temperature.Have invigorate blood circulation, effect such as circulation of qi promoting, pain relieving.
Aforementioned pharmaceutical compositions of the present invention when being prepared into pharmaceutically dosage form, can add conventional medicine excipient, for example solvent, binding agent, filler, disintegrating agent, antiseptic, solubilizing agent etc.
Aforementioned pharmaceutical compositions of the present invention according to the preparation process of routine, can be made any pharmaceutical dosage form that is suitable for clinical use, for example unguentum, powder, pill, tablet, capsule etc.
The method for making that pharmaceutical composition of the present invention is made unguentum is:
Oleum Fructus Bruceae 15～25% Rhizoma Corydalis extracts 9～15%
Stearic acid 5～10% glyceryl monostearates 1～5%
Liquid Paraffin 1～8% vaseline 0.5～2%
Lanoline 1～5% triethanolamine 0.1～0.5%
Ethyl hydroxybenzoate 0.1～0.5% distilled water 40～60%
Get stearic acid, glyceryl monostearate, vaseline, lanoline, liquid Paraffin by weight percentage and put in the container, after heating is dissolved in the water-bath, oil phase, continue to be heated to 70 ℃～80 ℃; Other gets triethanolamine, ethyl hydroxybenzoate and distilled water, is heated to 70 ℃～80 ℃, and the Rhizoma Corydalis extract is added, and stirs evenly, and gets water; The Fel Anas domestica seed oil is added mixing in the oil phase, with oil, the biphase mixing under agitation of water, constantly be stirred to cooling, promptly immediately.
The indication of medicine of the present invention is:
Be used for dysfunctional uterine bleeding, symptom is: the confusion of the menstrual cycle, menstrual period are different in size, and are indefinite through measuring, metrorrhagia, even massive hemorrhage.Or menstrual cycle shortens menostaxis etc.
The advantage of medicine of the present invention is the endometrium that pharmaceutical preparation targeting of the present invention directly is positioned over pathological changes, disposable placement treatment anovulatory dysfunctional uterine hemorrhage, the new way of having opened up the treatment by Chinese herbs anovulatory dysfunctional uterine hemorrhage.Has good haemostatic effect.Short treating period, determined curative effect, haemostatic effect is fast, and anastalsis is strong, and is cheap, and it is convenient to use.
The clinical research of experimental example one Drug therapy dysfunctional uterine hemorrhage of the present invention
In the process of the present invention's development, the applicant uses compound recipe Oleum Fructus Bruceae Ointment in Treatment dysfunctional uterine hemorrhage and has carried out clinical preliminary observation with reference to the related content of national Bureau of Drugs Supervision " new drug (Chinese medicine) clinical guidance principle " and " obstetrics and gynecology " (sixth version).
1 object and method:
1.1 diagnostic criteria: (1) clinical manifestation is that menstrual cycle shortens, menostaxis, and menorrhagia, or menstrual period are different in size, irregular vagina bleeding, and in time, lacked, even bleed profusely for a long time.(2) gynecologial examination: uterus normal size or bigger, quality is medium, smooth surface, no tenderness.(3) pathologic finding: endometrium is the proliferative phase change, endometrial hyperplasia is long or endometrial secretion is bad and endometrium is grown asynchronous.
1.2 the object of observation: this group is totally 60 examples, is the outpatient, is divided into observation group and matched group at random.Seminar's 40 examples, matched group 20 examples.At aspect basically identicals such as age, the course of disease, the state of an illness and pathologic findings, feature does not relatively have significant difference (P＞0.05) between group between two groups.
1.3 using method: in the clean back of menstruation 2-3d, expose cervix uteri with vaginal speculum, medicine of the present invention is put into cavity of uterus through the cervix uteri mouth, the vaginal plugging sterile gauze takes out gauze and gets final product behind the 24h.Prohibitive life and bath in a tub during the treatment finish afterwards to carry out respectively in January, February efficacy evaluation the course of treatment.Because the similar medication of ametria intracavity still at present, so line space contrasts in vain, promptly matched group does not add any medicine.
1.4 curative effect determinate standard: (1) recovery from illness: after the control over bleeding, in continuous 3 months cycles, cycle and menstrual period are normal, and menstrual blood volume is few through amount normally or more normally, and hematochrome is more than 10g.Or climacteric women blood ends back menopause person.(2) effective: menstrual cycle, menstrual period, part subjective symptoms be improved significantly, oligemia, hematochrome is the above person of 8g.(3) invalid: above every improver that all do not have.
2 results:
| Total routine number | Recovery from illness | Effectively | Invalid | Total effective rate | |||||
| n | ％ | n | ％ | n | ％ | n | ％ | ||
| Observation group's matched group | 40 20 | 24 0 | 60 | 12 3 | 30 15 | 4 17 | 10 85 | 36 3 | 90 15 |
Total effective rate relatively has utmost point significant difference (P＜0.01) between two groups
The explanation of this paper data, Drug therapy dysfunctional uterine hemorrhage curative effect of the present invention affirms that short treating period is not found significant complications, the patient is easy to accept.
Experimental example two medicines of the present invention are dispeled the research of effect to rat Swiss cheese hyperplasia endometrium
Purpose: observe Fructus Bruceae extract Oleum Fructus Bruceae variable concentrations rat Swiss cheese hyperplasia endometrium is dispeled effect, clear and definite its dose-effect relationship is inquired into the mechanism that Oleum Fructus Bruceae is treated anovulatory dysfunctional uterine hemorrhage, so that provide reliable experimental evidence to clinical practice.
Method: 50 of healthy adult SD female rats are divided into 5 groups at random: A: normal control group, B: model control group, C: Oleum Fructus Bruceae small dose group, D: dosage group in the Oleum Fructus Bruceae, E: the heavy dose of group of Oleum Fructus Bruceae.A group rat only carries out switch abdomen operation technique, and postoperative rose with normal saline and irritates stomach in first day, continuous 16 days, put to death when the rat vagina smear shows proestrus.All the other four groups of rats are irritated stomach by the female phenol of bilateral ovaries excision compound ethylene, set up the animal model of endometrial hyperplasia.After making film and finishing, injecting normal saline in the B group rat uterine cavity, C, D, E group respectively in the uterine cavity injection little, in, heavy dose of Oleum Fructus Bruceae, all behind drug-injected into uterine cavity, put to death in 5 days.Take by weighing rat body weight, the uterus weight in wet base is calculated the uterus index, carries out endometrial tissue section om observation.
Experimental result:
1, Oleum Fructus Bruceae does not have influence (P＞0.05) to rat body weight
2, the blank group of model group animal uterus weight in wet base and uterus index all obviously increases (P＜0.01), and Fructus Bruceae line of oils rat uterus weight in wet base and uterus index are compared with model group all obvious reduction (P＜0.01) (P＜0.05)
3, Oleum Fructus Bruceae little, in, heavy dose of group compares between any two, between small dose group and middle dosage group and the heavy dose of group all variant (P＜0.05), not statistically significant (P＞0.05) between middle dosage group and heavy dose of the group.
4, endometrial tissue om observation result: rats in normal control group Uterine mucosa epithelium is complete, is the monolayer column, and the body of gland amount is many, and a matter is loose, and blood vessel is normal; Model control group rat uterus mucosal epithelium is complete, and inner membrance obviously thickens, and epithelial cell is high column, and the part epithelial cell is multiple layer, abundant glandular, and lumen of gland enlarges, and glandular epithelium is false multiple layer, and a matter is loose, and blood vessel is normal; The part or all of necrosis of three treatment group rat endometrium comes off, and organizational structure disappears, and gland structure is unclear or disappear, and what have only stays serosal layer, a large amount of neutrophil infiltration is arranged, Interstitial cell pyknosis, the congestion of blood vessel in the slough.
Conclusion:
1, Oleum Fructus Bruceae does not have influence to rat body weight.
2, Oleum Fructus Bruceae obviously descends the uterus weight in wet base of laboratory animal, and the uterus index reduces.
3, Oleum Fructus Bruceae is dispeled effect to rat Swiss cheese hyperplasia endometrium.
4, it is variant that Oleum Fructus Bruceae small dose group and middle dosage and heavy dose of group compare the rat endometrium effect of dispeling, and middle dosage and heavy dose of group compare the endometrial zero difference of dispeling.In conjunction with rat uterus om observation result, take all factors into consideration the drug safety problem, act as good so dispel rat endometrium with middle dosage group.
(4) specific embodiment
The invention will be further described below in conjunction with embodiment:
The present invention makes unguentum with following raw material and method for making:
Embodiment 1
Oleum Fructus Bruceae 15～25% Rhizoma Corydalis extracts 9～15%
Stearic acid 5～10% glyceryl monostearates 1～5%
Liquid Paraffin 1～8% vaseline 0.5～2%
Lanoline 1～5% triethanolamine 0.1～0.5%
Ethyl hydroxybenzoate 0.1～0.5% distilled water 40～60%
Get stearic acid, glyceryl monostearate, vaseline, lanoline, liquid Paraffin by weight percentage and put in the container, after heating is dissolved in the water-bath, oil phase, continue to be heated to 70 ℃～80 ℃; Other gets triethanolamine, ethyl hydroxybenzoate and distilled water, is heated to 70 ℃～80 ℃, and the Rhizoma Corydalis extract is added, and stirs evenly, and gets water; The Fel Anas domestica seed oil is added mixing in the oil phase, with oil, the biphase mixing under agitation of water, constantly be stirred to cooling, promptly immediately.
Embodiment 2
Oleum Fructus Bruceae 18～20% Rhizoma Corydalis extracts 10～13%
Stearic acid 5～10% glyceryl monostearates 1～5%
Liquid Paraffin 1～8% vaseline 0.5～2%
Lanoline 1～5% triethanolamine 0.1～0.5%
Ethyl hydroxybenzoate 0.1～0.5% distilled water 40～60%
Method for making is the same.
Claims (2)
1. a hemostatic medicine used for cavitas uteri is characterized in that this medicine is to be made by following raw material weight percentage ratio:
Oleum Fructus Bruceae 15～25% Rhizoma Corydalis extracts 9～15%.
2. a uterine according to claim 1 is characterized in that also adding in this medicine material the adjuvant that has percentage by weight to be with gynecological's medication of stopping blooding:
Stearic acid 6～8% glyceryl monostearates 3～5%
Liquid Paraffin 3～6% vaseline 1～1.5%
Lanoline 3～5% triethanolamine 0.3～0.5%
Ethyl hydroxybenzoate 0.3～0.5% distilled water 50～60%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610105022 CN1911280A (en) | 2006-08-10 | 2006-08-10 | Hemostatic medicine used for cavitas uteri |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610105022 CN1911280A (en) | 2006-08-10 | 2006-08-10 | Hemostatic medicine used for cavitas uteri |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1911280A true CN1911280A (en) | 2007-02-14 |
Family
ID=37720443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610105022 Pending CN1911280A (en) | 2006-08-10 | 2006-08-10 | Hemostatic medicine used for cavitas uteri |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1911280A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103550600A (en) * | 2013-11-20 | 2014-02-05 | 艾广凤 | Drug for treating dysfunctional uterine bleeding |
-
2006
- 2006-08-10 CN CN 200610105022 patent/CN1911280A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103550600A (en) * | 2013-11-20 | 2014-02-05 | 艾广凤 | Drug for treating dysfunctional uterine bleeding |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1943600B (en) | Medicinal composition containing American cockroach and its ethanol extract and new use | |
| CN101069726A (en) | Chinese medicine preparation of expelling toxin by cooling and eliminating damp and removing stasis, preparing method and use | |
| CN111297910A (en) | Application of maggot in preparing medicine for preventing and treating hyperplasia of mammary glands | |
| CN1058184C (en) | Gynaecologist's hemostatic | |
| CN1911280A (en) | Hemostatic medicine used for cavitas uteri | |
| CN104706919B (en) | A kind of pharmaceutical composition for the treatment of ulcer in body surface | |
| CN110812463A (en) | Traditional Chinese medicine enema for treating pelvic inflammation and preparation method thereof | |
| CN101698037B (en) | Medicine for treating uterine bleeding and preparation process thereof | |
| CN1911281A (en) | Medicine for treating cervix erosio | |
| CN104888153A (en) | Traditional Chinese medicine preparation for treating hepatic hemangioma and preparation method therefor | |
| CN104367946A (en) | Traditional Chinese medicine suppository for treating chronic endometritis and preparation method thereof | |
| CN110302310A (en) | A kind of antimicrobial form composing prescription preparation and preparation method thereof | |
| CN115025108B (en) | A pharmaceutical composition for treating pelvic inflammatory disease and preparation method thereof | |
| CN116270828B (en) | Traditional Chinese medicine composition for wound healing and preparation method thereof | |
| CN100336553C (en) | Externally applied medicine for treating uterine erosion and its preparing method | |
| CN103784653B (en) | It is a kind of to treat pharmaceutical composition of sequelae of pelvic inflammatory disease and its production and use | |
| CN103372063B (en) | Traditional Chinese medicine composition for treating sequelae of pelvic inflammatory disease and use thereof | |
| CN111905002B (en) | Traditional Chinese medicine preparation for treating sequelae of pelvic inflammatory disease and preparation method and application thereof | |
| CN102698126B (en) | Traditional Chinese medicine compound having effect of treating prostatitis and preparation method thereof | |
| Zheng et al. | Analysis of the Effect of Shenghua Zhuyu Herbal Acupoint Plaster in the Treatment of Postpartum Malodor | |
| Zhongxing et al. | Therapeutic effects of traditional Chinese medicine in patients with symptomatic cervical ectopy | |
| CN106822524B (en) | Compound medicine for treating infertility and preparation method and application thereof | |
| CN118453801A (en) | Traditional Chinese medicine composition for treating endometriosis and preparation method thereof | |
| CN105250711A (en) | Traditional Chinese medicine composition for treating abdominal incision induration after cesarean delivery operation | |
| CN1839980A (en) | Medicine for treating gynecopathy and cypridopathy and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |